Patient Leaflet Updated 12-Dec-2025 | Janssen-Cilag Ltd (a Johnson & Johnson Company)
TALVEY
Talvey 2 mg/mL solution for injection
Talvey 40 mg/mL solution for injection
talquetamab
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What Talvey is and what it is used for
2. What you need to know before you are given Talvey
3. How Talvey is given
4. Possible side effects
5. How to store Talvey
6. Contents of the pack and other information
Talvey is a cancer medicine that contains the active substance talquetamab. Talquetamab is an antibody, a type of protein that recognises and attaches to specific targets in your body. It has been designed to attach to the protein GPRC5D (G Protein-coupled receptor family C group 5 member D), which is found on multiple myeloma cancer cells, and to cluster of differentiation 3 (CD3), a protein on T cells (a type of white blood cell). T cells are a part of the body’s natural defences and help protect the body from infection. They can also destroy cancer cells. When this medicine attaches to these cells, it brings the cancer cells and T cells together. This encourages the T cells to destroy the multiple myeloma cancer cells.
Talvey is used to treat adults with multiple myeloma, a cancer of the bone marrow.
It is used when patients have had at least three other types of treatment that have not worked or have stopped working.
Do not use Talvey if the above applies to you. If you are not sure, talk to your doctor or nurse before you are given Talvey.
Talk to your doctor or nurse before you are given Talvey.
Serious side effects
There are serious side effects that may occur after you start taking Talvey. You need to tell your doctor or nurse straight away if these occur, as they may require that you get immediate medical attention.
Tell your doctor or nurse right away if you experience any of the following:
Talvey and vaccines
Talk to your doctor or nurse before you are given Talvey if you have had a recent vaccination or are going to have a vaccination. Your immune system (the body’s natural defences) may not respond as well to vaccination when you are taking this medicine.
You should not receive live vaccines, a specific type of vaccine, from at least 4 weeks before starting your treatment with Talvey until at least 4 weeks after you have taken your last dose.
Tests and checks
Before you are given Talvey your doctor will check your blood to look at the levels of different blood cells and to test for signs of infection. Infections will be treated before you start taking this medicine.
After you have Talvey your doctor will monitor you for side effects. They will also regularly check your blood counts, as the number of blood cells and other blood components may decrease when you use this medicine.
Talvey should not be used in children or young people below 18 years of age, because the medicine has not been studied in this age group and it is not known how this medicine will affect them.
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.
This includes medicines you can get without a prescription and herbal medicines.
Pregnancy and contraception
Talvey has the potential to be transmitted from the mother to the developing foetus. The effects of Talvey on the developing foetus are unknown and a risk to newborns/infants cannot be excluded.
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or nurse for advice before you are given this medicine.
If you become pregnant while being treated with this medicine, tell your doctor or nurse straight away.
If you could become pregnant, you must use effective contraception during treatment and for 3 months after stopping treatment with Talvey. Your doctor will check if you are pregnant before starting treatment.
If your partner becomes pregnant while you are taking this medicine, tell your doctor straight away.
If you have taken this medicine during pregnancy, your newborn baby should not be given any live vaccines until he or she is at least four weeks old.
Breast-feeding
It is not known if Talvey passes into breast milk. There may be a risk to breastfed newborns/infants. Ask your doctor for advice before starting this medicine. You and your doctor will decide if the benefit of breast-feeding is greater than the risk to your baby. If you and your doctor decide to stop taking this medicine, you should not breast-feed for 3 months after stopping treatment.
Fertility
There are no data on the effect of talquetamab on fertility. Effects of talquetamab on male and female fertility have not been evaluated in animal studies
Some people may feel tired, dizzy, or confused while taking Talvey. Do not drive, use tools or machines from recieving your first dose until at least 48 hours after receiving your first treatment dose of Talvey or as instructed by your doctor.
Talvey contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.
Talvey will be given to you under supervision by a doctor experienced in treating patients with multiple myeloma. Your doctor will decide how much Talvey you are given. The dose of Talvey will depend on your body weight.
Talvey is given either once a week or once every 2 weeks, depending on the dose, as follows:
0.4 mg/kg once a week:
Your doctor will monitor you for side effects after each of your first three doses. They will do this for 2 days after each dose. You should stay close to a healthcare facility after each of the first three doses in case you have side effects.
If you experience side effects after any of your first two doses, your doctor may decide to wait up to 7 days before giving you your next dose.
0.8 mg/kg once every 2 weeks:
Your doctor will monitor you for side effects after each of your first four doses. They will do this for 2 days after each dose. You should stay close to a healthcare facility after each of the first four doses in case you have side effects.
If you experience side effects after any of your first three doses, your doctor may decide to wait up to 7 days before giving you your next dose.
The decision to use either the 0.4 mg/kg once weekly or 0.8 mg/kg every two weeks should be made in consultation with your doctor.
Talvey will be given to you by a doctor or nurse as an injection under your skin (‘subcutaneous’ injection). It is given in the stomach area (abdomen) or thigh.
Medicines given during treatment with Talvey
Before the first three doses (if you are given 0.4 mg/kg bodyweight) or the first four doses (if you are given 0.8 mg/kg bodyweight) of Talvey, you will be given medicines which help to lower the chance of side effects. These may include:
You may also be given these medicines for when you take later doses of Talvey based on any symptoms you have.
You may also be given additional medicines based on any symptoms you experience or your medical history.
This medicine will be given by your doctor or nurse. In the event that you are given too much (an overdose) your doctor will check you for side effects.
It is very important to go to all your appointments to make sure your treatment works. If you miss an appointment, make another one as soon as possible.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Get medical help straight away if you get any of the following serious side effects which may be severe and can be fatal.
Very Common (may affect more than 1 in 10 people):
Tell your doctor right away if you notice any of the above listed serious side effects.
Other side effects are listed below. Tell your doctor or nurse if you get any of these side effects.
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people)
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Talvey will be stored at the hospital or clinic by your doctor. The following information is therefore mainly intended for healthcare professionals.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and vial label after “EXP”. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C to 8°C). Do not freeze.
Store in the original carton in order to protect from light.
Before using the medicine, check the solution for particles or discolouration. The solution should be colourless to light yellow. Do not use this medicine if it is cloudy, discoloured, or contains visible particles.
Medicines should not be disposed of via wastewater or household waste. Your healthcare professional will throw away any medicines that are no longer being used. These measures will help protect the environment.
Talvey is a solution for injection (injection) and is a colourless to light yellow liquid.
Talvey is supplied as a carton pack containing 1 glass vial.
This leaflet was last revised in November 2025
This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.
The National Health Authority will review new information on this medicine at least every year and this leaflet will be updated as necessary.
50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
+44 (0) 1494 567 445
+44 (0)1494 567 568
+44 (0)800 731 5550
+44 (0)1494 567 567
https://innovativemedicine.jnj.com/uk/
+44 (0)800 731 8450